<p>Summit Therapeutics Inc.（纳斯达克代码：SMMT - 获取免费报告）周一股价下跌 5.4%。该股最低交易价为 20.00 美元，最后交易价为 20.34 美元。在交易过程中，约有 583,844 股成交，较日均成交量 2,401,488 股下降了 76%。该股此前收盘价为 21.50 美元。</p>
<p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
<p>多家研究机构对 SMMT 发布了报告。HC Wainwright 在 1 月 21 日的报告中重申了对 Summit Therapeutics 的 “买入” 评级，并设定了 44.00 美元的目标价。Truist Financial 在 1 月 8 日的研究报告中开始覆盖 Summit Therapeutics，给予 “买入” 评级，目标价为 35.00 美元。Jefferies Financial Group 在 12 月 6 日的研究报告中开始覆盖 Summit Therapeutics，设定了 “买入” 评级和 31.00 美元的目标价。JMP Securities 在 11 月 4 日的研究报告中开始覆盖 Summit Therapeutics，给予 “市场表现优于大盘” 评级，目标价为 32.00 美元。最后，Wells Fargo &amp; Company 在 12 月 11 日的研究报告中开始覆盖 Summit Therapeutics，设定了 “增持” 评级和 30.00 美元的目标价。一位分析师对该股给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股的平均评级为 “适度买入”，共识目标价为 33.57 美元。</p>
<p><strong>获取我们关于 SMMT 的最新报告</strong></p>
<h2>Summit Therapeutics 股票表现</h2>
<ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则改变者吗？</li>
</ul>
<p>该公司的市值为 153.2 亿美元，市盈率为-74.21，贝塔值为-0.88。该公司的 50 日移动平均价格为 19.19 美元，200 日移动平均价格为 18.11 美元。</p>
<h2>对 Summit Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金最近增加或减少了对 SMMT 的持股。Baker BROS. Advisors LP 在第三季度将其在 Summit Therapeutics 的持股增加了 5.2%。Baker BROS. Advisors LP 目前持有该公司 24,424,865 股股票，价值 534,905,000 美元，在上个季度又购买了 1,202,643 股。abrdn plc 在第三季度获得了 Summit Therapeutics 的新头寸，价值 24,885,000 美元。FMR LLC 在第三季度将其在 Summit Therapeutics 的持股增加了 9.8%。FMR LLC 目前持有该公司 8,303,119 股股票，价值 181,838,000 美元，在上个季度又购买了 737,692 股。Charles Schwab Investment Management Inc.在第三季度将其在 Summit Therapeutics 的持股增加了 53.3%。Charles Schwab Investment Management Inc.目前持有该公司 1,432,713 股股票，价值 31,376,000 美元，在上个季度又购买了 497,984 股。最后，Principal Financial Group Inc.在第四季度将其在 Summit Therapeutics 的持股增加了 252.8%。Principal Financial Group Inc.目前持有该公司 205,150 股股票，价值 3,661,000 美元，在上个季度又购买了 147,003 股。目前，4.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Summit Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<ul>
<li>Summit Therapeutics 因试验结果飙升：现在是买入时机吗？</li>
</ul>
<p>Summit Therapeutics Inc.是一家生物制药公司，专注于在美国和英国发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法。该公司的主要开发候选药物是 Ivonescimab，一种通过阻断 PD-1 与抗血管生成相结合的免疫疗法双特异性抗体；其抗感染产品组合包括 SMT-738，一种用于治疗多重耐药感染的新型精准抗生素，主要包括耐碳青霉烯类的肠杆菌科感染。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Summit Therapeutics 更好</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>3 只必备 ETF 将在本季度主导市场</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>寻求稳定？这 3 只股票提供强劲潜力</li>
<li>如何投资蓝筹股</li>
<li>贸易战便宜股票：三大精选不容错过</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
<p>在你考虑 Summit Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Summit Therapeutics 并不在名单上。</p>
<p>虽然 Summit Therapeutics 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Summit治疗

<p>Summit Therapeutics（纳斯达克代码：SMMT）股价下跌 5.4%，至 20.34 美元，交易量较平均水平下降 76%。分析师们对其前景持积极态度，多家机构给予 “买入” 评级，目标价格范围在 30 美元至 44 美元之间。该股票的平均评级为 “适度买入”，共识目标价格为 33.57 美元。对冲基金也调整了在该公司的持股，该公司专注于开发针对各种医疗条件的疗法，包括用于免疫治疗的双特异性抗体和精准抗生素</p>

<p>Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) shares dropped 5.4% on Monday . The stock traded as low as $20.00 and last traded at $20.34. Approximately 583,844 shares traded hands during trading, a decline of 76% from the average daily volume of 2,401,488 shares. The stock had previously closed at $21.50.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.（纳斯达克代码：SMMT - 获取免费报告）周一股价下跌 5.4%。该股最低交易价为 20.00 美元，最后交易价为 20.34 美元。在交易过程中，约有 583,844 股成交，较日均成交量 2,401,488 股下降了 76%。该股此前收盘价为 21.50 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
</div><p>A number of research firms have issued reports on SMMT. HC Wainwright reiterated a &#34;buy&#34; rating and set a $44.00 target price on shares of Summit Therapeutics in a report on Tuesday, January 21st. Truist Financial began coverage on Summit Therapeutics in a research note on Wednesday, January 8th. They issued a &#34;buy&#34; rating and a $35.00 price objective on the stock. Jefferies Financial Group started coverage on Summit Therapeutics in a research note on Friday, December 6th. They set a &#34;buy&#34; rating and a $31.00 target price for the company. JMP Securities started coverage on Summit Therapeutics in a research report on Monday, November 4th. They issued a &#34;market outperform&#34; rating and a $32.00 price target on the stock. Finally, Wells Fargo &amp; Company began coverage on Summit Therapeutics in a research report on Wednesday, December 11th. They set an &#34;overweight&#34; rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.57.</p>
<div class="lb-trans"><p>多家研究机构对 SMMT 发布了报告。HC Wainwright 在 1 月 21 日的报告中重申了对 Summit Therapeutics 的 “买入” 评级，并设定了 44.00 美元的目标价。Truist Financial 在 1 月 8 日的研究报告中开始覆盖 Summit Therapeutics，给予 “买入” 评级，目标价为 35.00 美元。Jefferies Financial Group 在 12 月 6 日的研究报告中开始覆盖 Summit Therapeutics，设定了 “买入” 评级和 31.00 美元的目标价。JMP Securities 在 11 月 4 日的研究报告中开始覆盖 Summit Therapeutics，给予 “市场表现优于大盘” 评级，目标价为 32.00 美元。最后，Wells Fargo &amp; Company 在 12 月 11 日的研究报告中开始覆盖 Summit Therapeutics，设定了 “增持” 评级和 30.00 美元的目标价。一位分析师对该股给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat.com 的数据，该股的平均评级为 “适度买入”，共识目标价为 33.57 美元。</p>
</div><p><strong>Get Our Latest Report on SMMT</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 SMMT 的最新报告</strong></p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表现</h2>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则改变者吗？</li>
</ul>
</div><p>The firm has a market capitalization of $15.32 billion, a price-to-earnings ratio of -74.21 and a beta of -0.88. The company has a 50-day moving average price of $19.19 and a 200-day moving average price of $18.11.</p>
<div class="lb-trans"><p>该公司的市值为 153.2 亿美元，市盈率为-74.21，贝塔值为-0.88。该公司的 50 日移动平均价格为 19.19 美元，200 日移动平均价格为 18.11 美元。</p>
</div><h2>Hedge Funds Weigh In On Summit Therapeutics</h2>
<div class="lb-trans"><h2>对 Summit Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in SMMT. Baker BROS. Advisors LP boosted its holdings in shares of Summit Therapeutics by 5.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 24,424,865 shares of the company's stock valued at $534,905,000 after buying an additional 1,202,643 shares in the last quarter. abrdn plc acquired a new position in Summit Therapeutics in the third quarter valued at $24,885,000. FMR LLC boosted its stake in Summit Therapeutics by 9.8% in the third quarter. FMR LLC now owns 8,303,119 shares of the company's stock valued at $181,838,000 after acquiring an additional 737,692 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Summit Therapeutics by 53.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,432,713 shares of the company's stock worth $31,376,000 after purchasing an additional 497,984 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Summit Therapeutics by 252.8% in the 4th quarter. Principal Financial Group Inc. now owns 205,150 shares of the company's stock valued at $3,661,000 after purchasing an additional 147,003 shares during the last quarter. 4.61% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对 SMMT 的持股。Baker BROS. Advisors LP 在第三季度将其在 Summit Therapeutics 的持股增加了 5.2%。Baker BROS. Advisors LP 目前持有该公司 24,424,865 股股票，价值 534,905,000 美元，在上个季度又购买了 1,202,643 股。abrdn plc 在第三季度获得了 Summit Therapeutics 的新头寸，价值 24,885,000 美元。FMR LLC 在第三季度将其在 Summit Therapeutics 的持股增加了 9.8%。FMR LLC 目前持有该公司 8,303,119 股股票，价值 181,838,000 美元，在上个季度又购买了 737,692 股。Charles Schwab Investment Management Inc.在第三季度将其在 Summit Therapeutics 的持股增加了 53.3%。Charles Schwab Investment Management Inc.目前持有该公司 1,432,713 股股票，价值 31,376,000 美元，在上个季度又购买了 497,984 股。最后，Principal Financial Group Inc.在第四季度将其在 Summit Therapeutics 的持股增加了 252.8%。Principal Financial Group Inc.目前持有该公司 205,150 股股票，价值 3,661,000 美元，在上个季度又购买了 147,003 股。目前，4.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Summit Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Summit Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Summit Therapeutics Surges on Trial Results: Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics 因试验结果飙升：现在是买入时机吗？</li>
</ul>
</div><p>Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.是一家生物制药公司，专注于在美国和英国发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法。该公司的主要开发候选药物是 Ivonescimab，一种通过阻断 PD-1 与抗血管生成相结合的免疫疗法双特异性抗体；其抗感染产品组合包括 SMT-738，一种用于治疗多重耐药感染的新型精准抗生素，主要包括耐碳青霉烯类的肠杆菌科感染。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>3 Must-Have ETFs Set to Dominate This Quarter</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Seeking Stability? These 3 Stocks Offer Strong Potential</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Summit Therapeutics 更好</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>3 只必备 ETF 将在本季度主导市场</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>寻求稳定？这 3 只股票提供强劲潜力</li>
<li>如何投资蓝筹股</li>
<li>贸易战便宜股票：三大精选不容错过</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Summit Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Summit Therapeutics 并不在名单上。</p>
</div><p>While Summit Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Summit Therapeutics 目前在分析师中获得了 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Summit 治疗 (NASDAQ:SMMT) 股价下跌 5.4% - 以下是原因